Union Korea Pharm Capital Reduction New Share Listing Delayed to July 29, Administrative Delay
Union Korea Pharm filed a correction report for its capital reduction decision, postponing the new share listing date from July 22 to July 29.
The delay is due to administrative procedures with the depository, while key terms such as the 66.67% reduction ratio and the resulting 19,854,006 outstanding shares remain unchanged.
The capital reduction involves a 3:1 reverse stock split of existing shares, aimed at improving the financial structure under the rehabilitation plan, and will be followed by a debt-to-equity swap and a third-party allotment capital increase.
Fractional shares will be canceled without compensation by the administrator with court approval. Further schedule changes will be disclosed if they occur.
[AI Summary]The delay in the listing date for the capital reduction is a minor administrative schedule adjustment. The fundamental terms of the rehabilitation plan, including the reduction ratio and the scale of the debt-to-equity swap, remain unchanged, limiting the impact on the stock price. Investors should focus on the upcoming third-party allotment capital increase and other capital changes rather than the listing schedule.
KOSDAQ Filing Information
[Correction of Description] Report on Major Matters (Decision on Capital Reduction)